Mechanism of Action
In the natural life cycle of the human immunodeficiency virus, a specific enzyme called HIV aspartyl protease plays a critically important role. Its main task is to cleave large precursor polypeptide chains (gag and pol polyproteins) synthesized from viral messenger RNA.
After the protease cleaves these large molecules, individual structural elements and key functional proteins are formed within the viral particle: reverse transcriptase, integrase, and the protease itself. Without this process, the proper assembly and final maturation of a functional virion are impossible.
Protease inhibitor drugs act by competitively binding to the active site of this enzyme. As a result, aspartyl protease is inactivated, polyproteins remain uncleaved, and defective, "immature" viral particles are formed. These virions completely lose their ability to infect new host cells.
Representatives and Pharmacokinetic Features
This class of antiretroviral agents was introduced into clinical practice in the mid-1990s. Historically, the first representative was saquinavir. Other drugs were subsequently developed: ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, and atazanavir. For patient convenience, fixed-dose combinations are available, such as Kaletra, which is a fixed combination of lopinavir and ritonavir.
Most protease inhibitors share common pharmacokinetic properties. They feature a high degree of plasma protein binding and undergo metabolic inactivation in the liver. The key enzyme responsible for their metabolism is the CYP3A4 isoenzyme. Furthermore, these drugs can actively inhibit this isoenzyme, leading to a high propensity for drug-drug interactions.
Standard dosing regimens for these drugs require frequent administration—three times daily or even more often. Gastrointestinal absorption is notably affected by food intake. As a general rule, food improves the bioavailability of most protease inhibitors. Specifically, nelfinavir is strongly recommended to be taken with a fatty meal. However, an important exception to this rule is indinavir. The presence of food, especially high-fat food, drastically reduces its absorption (by 75%), so this drug must be taken strictly on an empty stomach or with a very light meal.
The "Boosting" Effect of Ritonavir
Among all drugs in this class, ritonavir plays a unique role. Its main feature is that it causes the most potent inhibition of the CYP3A4 isoenzyme in both the liver and the intestinal wall. Due to this property, ritonavir is used today in low doses not primarily as an independent antiviral agent, but as a powerful pharmacokinetic enhancer (the "booster" effect) in combination with other protease inhibitors.
The mechanism of this enhancement involves reducing the presystemic elimination of the primary drug. Ritonavir slows down the metabolism of the concomitant medication, leading to a significant increase in its bioavailability and a prolongation of its therapeutic action. This is especially critical for drugs with a short half-life. The clinical benefit is clear: combination with ritonavir allows for lower doses of other antiretrovirals and a reduction in dosing frequency to once or twice daily.
The only exception to this approach is nelfinavir. It is metabolized primarily by other isoenzymes (CYP3A4 plays a minor role) and forms its own active metabolite during biotransformation. For this reason, nelfinavir is never co-administered with ritonavir.
Clinical Application and Adverse Reactions
Protease inhibitors are widely used to treat HIV infection in both adult and pediatric patients. A mandatory condition for their use is administration as part of combination antiretroviral therapy (cART)—they are always used concurrently with reverse transcriptase inhibitors.
The safety profile of these drugs includes several characteristic adverse effects. Patients most frequently encounter gastrointestinal issues: abdominal pain, diarrhea, nausea, and vomiting. Fortunately, these symptoms are usually transient and completely resolve about a month after therapy initiation.
However, with long-term use, serious metabolic and organ-specific complications come to the forefront:
- Lipid metabolism: Elevated levels of atherogenic lipoproteins in the blood.
- Carbohydrate metabolism: Development of hyperglycemia, significantly increasing the risk of diabetes mellitus.
- Fat distribution: Lipodystrophy develops (a specific redistribution of body fat).
- Kidneys: Increased risk of nephrolithiasis (kidney stones).
- Liver: Hepatotoxicity, requiring monitoring of hepatic function.